BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25:801-9. [PMID: 18670741 DOI: 10.1007/s12325-008-0082-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
2 Thongsom S, Chaocharoen W, Silsirivanit A, Wongkham S, Sripa B, Choe H, Suginta W, Talabnin C. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016;37:9451-9463. [PMID: 26781979 DOI: 10.1007/s13277-016-4838-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
3 Jeet V, Tevz G, Lehman M, Hollier B, Nelson C. Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells. Endocr Relat Cancer 2014;21:723-37. [PMID: 24981110 DOI: 10.1530/ERC-14-0267] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
4 Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet 2013;287:111-5. [PMID: 22945838 DOI: 10.1007/s00404-012-2546-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
5 Wan G, Xiang L, Sun X, Wang X, Li H, Ge W, Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget 2017;8:5382-91. [PMID: 28036271 DOI: 10.18632/oncotarget.14280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
6 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
7 Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8. [PMID: 19134206 DOI: 10.1186/1471-2407-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
8 Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol 2016;140:64-9. [PMID: 26607777 DOI: 10.1016/j.ygyno.2015.11.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
9 Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384. [PMID: 24801872 DOI: 10.1371/journal.pone.0096384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
10 Shaker OG, Elbaz EM. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females. Asian Pac J Cancer Prev 2020;21:355-61. [PMID: 32102511 DOI: 10.31557/APJCP.2020.21.2.355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int 2013;33:341-6. [PMID: 22451025 DOI: 10.1007/s00296-012-2387-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
12 Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, Zhao L, Jiang X, Yuan LJ. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. Braz J Med Biol Res 2012;45:264-72. [PMID: 22267006 DOI: 10.1590/s0100-879x2012007500010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
13 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
15 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
16 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
17 Kahramanoğlu İ, Tokgözoğlu N, Turan H, Şal V, Şimşek G, Gelişgen R, Beşe T, Demirkıran F, Arvas M, Uzun H. YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer. Turk J Obstet Gynecol 2018;15:177-81. [PMID: 30202628 DOI: 10.4274/tjod.28459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
19 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
20 Artlett CM. The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis? Immunology Letters 2018;195:30-7. [DOI: 10.1016/j.imlet.2017.11.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
21 Scully S, Yan W, Bentley B, Cao QJ, Shao R. Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PLoS One 2011;6:e25819. [PMID: 21991364 DOI: 10.1371/journal.pone.0025819] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
22 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
23 Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, Wagrodzki M, Kowalska M. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2017;215:141-7. [PMID: 28624692 DOI: 10.1016/j.ejogrb.2017.06.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]